Evidence map›Paper›PMID 40943069›Full record

ReviewInternational journal of molecular sciences2025

Cell-Based Drug Delivery Systems: Innovative Drug Transporters for Targeted Therapy.

Shynggys Sergazy, Kulzhan Berikkhanova, Alexandr Gulyayev, Zarina Shulgau, Assiya Maikenova, Ruslan Bilal, Milan Terzic, Zhaxybay Zhumadilov, Mohamad Aljofan

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shynggys SergazyNational Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan.ORCID 0000-0002-6030-620X
Kulzhan BerikkhanovaNational Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan.
Alexandr GulyayevNational Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan.
Zarina ShulgauNational Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan.ORCID 0000-0001-8148-0816
Assiya MaikenovaNational Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan.ORCID 0009-0005-6338-6099
Ruslan BilalSchool of Medicine, Nazarbayev University, Astana 010000, Kazakhstan.
Milan TerzicSchool of Medicine, Nazarbayev University, Astana 010000, Kazakhstan.ORCID 0000-0003-3914-5154
Zhaxybay ZhumadilovSchool of Medicine, Nazarbayev University, Astana 010000, Kazakhstan.
Mohamad AljofanNational Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan.

Funding

Nazarbayev University under Collaborative Research Program Grant 211123CRP1614Science Committee of the Ministry of Higher Education and Science of the Republic of Kazakhstan AP19676272
6 · The paper itself

Abstract

Significant progress has been made in developing cell-based drug delivery systems that utilize the intrinsic biological properties of various cell types-erythrocytes, leukocytes, platelets, stem cells, and even spermatozoa-to improve drug targeting, bioavailability, and biocompatibility. This review presents an integrative analysis of the latest advances in cell-based drug delivery systems, focusing on their design, pharmacokinetics, cellular interactions, and therapeutic potential. We specifically focus on hybrid microrobots and membrane-coated nanocarriers as emerging biohybrid platforms. Despite these advances, translation to the clinical phase remains constrained by persistent limitations, such as immune clearance, loss of membrane integrity during cargo loading, limited tissue penetration of carrier cells, and manufacturing challenges. Finally, we highlight future directions, including CAR-cell combinations and artificial cell engineering, that promise to expand the clinical utility of cell-based drug delivery systems in oncology, infectious diseases, and regenerative medicine.

Indexed as

Drug Delivery SystemsAnimalsDrug CarriersHumansDrug Carrierscell-based drug deliveryerythrocyte carriersleukocyte delivery systemsplatelet biomimeticstargeted transport

Identifiers

PMID40943069
PMCPMC12428288

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.